Literature DB >> 9635840

Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.

S Kennedy1, M J Duffy, C Duggan, C Barnes, R Rafferty, M D Kramer.   

Abstract

Urokinase plasminogen activator (uPA) is a serine protease involved in cancer invasion and metastasis. uPA acts in vivo by binding to a membrane receptor known as uPAR. In this study, uPA and uPAR levels were semiquantitated by immunocytochemistry in 36 primary breast carcinomas. Using monoclonal antibody HD-UK 1, uPA was detected both in stromal and in malignant cells. However, the predominant location was in the stromal cells. Using double-staining, cells containing uPA were also found to coexpress either cytokeratin (an epithelial cell marker) or more frequently KP1 (a macrophage/monocyte cell marker). With monoclonal antibody HD-uPAR 13.1, uPAR was localized principally to spindle- or macrophage-like stromal cells, especially when these cells surrounded invasive breast cancer. In contrast, uPAR was only rarely detected in cancer cells and was not detected in normal epithelia surrounding tumour or in areas of adenosis. uPA levels in both stromal and epithelial cells were significantly correlated with those for uPAR. We conclude that both uPA and its receptor are mostly present in stromal cells in invasive breast carcinomas. These results suggest that stromal cells collaborate with malignant cells to mediate metastasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9635840      PMCID: PMC2150065          DOI: 10.1038/bjc.1998.268

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

Authors:  T J de Vries; P H Quax; M Denijn; K N Verrijp; J H Verheijen; H W Verspaget; U H Weidle; D J Ruiter; G N van Muijen
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

2.  Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.

Authors:  S Del Vecchio; M P Stoppelli; M V Carriero; R Fonti; O Massa; P Y Li; G Botti; M Cerra; G D'Aiuto; G Esposito
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

3.  Plasminogen activation in healing human wounds.

Authors:  B M Schäfer; K Maier; U Eickhoff; R F Todd; M D Kramer
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

4.  Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA.

Authors:  W M Mars; R Zarnegar; G K Michalopoulos
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

5.  Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.

Authors:  J Jankun; H W Merrick; P J Goldblatt
Journal:  J Cell Biochem       Date:  1993-10       Impact factor: 4.429

6.  Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.

Authors:  F Jänicke; M Schmitt; L Pache; K Ulm; N Harbeck; H Höfler; H Graeff
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue.

Authors:  E Bianchi; R L Cohen; A T Thor; R F Todd; I F Mizukami; D A Lawrence; B M Ljung; M A Shuman; H S Smith
Journal:  Cancer Res       Date:  1994-02-15       Impact factor: 12.701

8.  Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.

Authors:  C Pyke; N Graem; E Ralfkiaer; E Rønne; G Høyer-Hansen; N Brünner; K Danø
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

9.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

Authors:  C Pyke; P Kristensen; E Ralfkiaer; J Grøndahl-Hansen; J Eriksen; F Blasi; K Danø
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

Review 10.  Proteases as prognostic markers in cancer.

Authors:  M J Duffy
Journal:  Clin Cancer Res       Date:  1996-04       Impact factor: 12.531

View more
  6 in total

Review 1.  The macrophage growth factor CSF-1 in mammary gland development and tumor progression.

Authors:  Elaine Y Lin; Valerie Gouon-Evans; Andrew V Nguyen; Jeffrey W Pollard
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

2.  Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.

Authors:  E Dublin; A Hanby; N K Patel; R Liebman; D Barnes
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor.

Authors:  Anthony F Rullo; Kelly J Fitzgerald; Viswanathan Muthusamy; Min Liu; Cai Yuan; Mingdong Huang; Minsup Kim; Art E Cho; David A Spiegel
Journal:  Angew Chem Int Ed Engl       Date:  2016-02-16       Impact factor: 15.336

4.  Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture.

Authors:  Edson Mantovani Barbosa; Sueli Nonogaki; Maria Lucia Hirata Katayama; Maria Aparecida Azevedo Koike Folgueira; Venâncio Ferreira Avancini Alves; Maria Mitzi Brentani
Journal:  Virchows Arch       Date:  2003-12-02       Impact factor: 4.064

5.  Expression of proteinases and inhibitors in human breast cancer progression and survival.

Authors:  E A Baker; T J Stephenson; M W R Reed; N J Brown
Journal:  Mol Pathol       Date:  2002-10

6.  Tumor-associated soluble uPAR-directed endothelial cell motility and tumor angiogenesis.

Authors:  J S Rao; M Gujrati; C Chetty
Journal:  Oncogenesis       Date:  2013-06-24       Impact factor: 7.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.